- Home
- INVA vs AAPG Comparison
INVA vs AAPG Comparison
Compare INVA & AAPG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | INVA | AAPG |
|---|---|---|
| Founded | 1996 | 2009 |
| Country | United States | China |
| Employees | N/A | 767 |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 2.0B |
| IPO Year | 2000 | N/A |
Fundamental Metrics
Financial Performance| Metric | INVA | AAPG |
|---|---|---|
| Price | $21.41 | $19.14 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | $32.80 | ★ $48.40 |
| AVG Volume (30 Days) | ★ 727.2K | 14.3K |
| Earning Date | 05-07-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 816.67 | N/A |
| EPS | ★ 2.22 | N/A |
| Revenue | ★ $217,217,000.00 | N/A |
| Revenue This Year | $8.95 | $290.34 |
| Revenue Next Year | $12.65 | N/A |
| P/E Ratio | $9.55 | ★ N/A |
| Revenue Growth | ★ 62.63 | N/A |
| 52 Week Low | $16.52 | $16.36 |
| 52 Week High | $25.15 | $48.45 |
Technical Indicators
Market Signals| Indicator | INVA | AAPG |
|---|---|---|
| Relative Strength Index (RSI) | 41.01 | 45.77 |
| Support Level | $20.56 | $16.64 |
| Resistance Level | $22.86 | $20.40 |
| Average True Range (ATR) | 0.48 | 0.54 |
| MACD | -0.09 | -0.01 |
| Stochastic Oscillator | 18.15 | 19.27 |
Price Performance
Historical ComparisonAbout INVA Innoviva Inc.
Innoviva Inc is a company with a portfolio of royalty healthcare assets. It has three primary sets of assets: a royalty portfolio, operating assets in critical care and infectious disease, and other strategic healthcare assets. Its product offering includes Relvar/Breo/Ellipta, Anoro, Trelegy, and others.
About AAPG Ascentage Pharma Group International American Depository Shares
Ascentage Pharma Group International is a clinical-stage biotechnology company engaged in the development and sales of novel small-scale therapies for cancers, hepatitis B virus, or HBV, and certain age-related diseases. It focuses on developing therapies that inhibit protein-protein interactions to restore apoptosis or programmed cell death. The Group has one reportable operating segment, which is discovering, developing, and commercializing therapies to address medical needs in hematological malignancies and currently has seven drug candidates in pipeline under research. The company's geographical segments include the United States and Mainland China.